AstraZeneca Aktie News

AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) is set to deliver a solid finish to 2025 when it reports fourth-quarter results next month, according to JP Morgan, which expects earnings to come in modestly ahead of market expectations and guidance for 2026 to underpin confidence in the growth outlook. The US bank forecasts fourth-quarter revenues of $15.5 billion, representing 2% growth at constant exch...

WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, the developer of the leading AI foundation model for tumor and immune biology, today announced a strategic collaboration with AstraZeneca, a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines in Oncology, Rare Diseases and BioPharmaceuticals, to advance oncology dru...

With a 58% gain, CVS Health had its best year since 1982—and it wasn't the only strong performer.

The festive period is, for some, a time for taking stock of what's happened in the past year - for others, though, its a time to pick stocks for the year ahead. So it is, then, that it's the season for looking ahead.

The pharmaceutical company said its ceralasertib combination didn't meet the primary goal of a late-stage clinical trial for advanced lung cancer.

AstraZeneca said on Monday that a late‑stage trial testing Imfinzi in combination with ceralasertib failed to improve overall survival in patients with previously treated advanced non‑small cell lung cancer.

The White House is getting ready to announce more deals with drugmakers aimed at lowering drug prices.

AstraZeneca targets $80bn revenue by FY2030, driven by oncology leadership and robust pipeline execution. AZN demonstrates double-digit revenue and EBITDA growth, trading at a discount to high-growth peers despite comparable operating leverage. DCF suggests limited upside under conservative assumptions, but peer-based multiples indicate substantial appreciation potential, supporting a GARP inve...